Researchers have identified a new biomarker that could fundamentally change how doctors predict outcomes and select therapies for patients with colorectal cancer. By focusing on the “microenvironment”—the complex ecosystem of non-tumor cells surrounding a malignancy—scientists have found a specific protein that signals whether a patient is likely to respond to certain treatments or face a more aggressive disease course.
The discovery centers on a protein called CTHRC1, found in a specific population of cancer-associated fibroblasts (CAFs). These connective tissue cells are not cancerous themselves, but they act as architects for the tumor, creating an environment that helps the cancer proliferate. According to a study published in the journal Gut, the presence of these CTHRC1(+) CAFs can serve as a precise new biomarker predicts prognosis and treatment response in colorectal cancer, offering a roadmap for personalized oncology.
This breakthrough is the result of a multidisciplinary effort involving pathologists, oncologists, and biologists from the Hospital del Mar Research Institute (HMRIB), the Institute for Research in Biomedicine (IRB Barcelona), and the CIBER Oncology area (CIBERONC). The team’s work suggests that by analyzing the stromal cells surrounding a tumor, clinicians can gain insights that the tumor cells alone cannot provide.
For patients, In other words a shift toward more accurate “precision medicine.” Rather than relying on broad categories of colorectal cancer, doctors may soon be able to employ this marker to determine if a patient is a candidate for immunotherapy or if they are likely to develop resistance to standard chemotherapy.
Decoding the Tumor Microenvironment
To reach this conclusion, the research team underwent a rigorous validation process to ensure the marker’s reliability. They first examined 17 different cohorts, analyzing samples from nearly 3,000 patients. This large-scale screening allowed the team to observe how different cell populations correlated with patient outcomes.
The process involved a sophisticated sequence of analysis:
- Single-cell RNA analysis: Researchers examined tumor cell RNA at the individual cell level to isolate the most promising cell populations.
- Protein Determination: Once the cell populations were identified, the team determined which specific proteins they expressed.
- Validation: Only the cells expressing the CTHRC1 protein retained consistent predictive capacity across the various patient groups.
The findings were further validated using patient samples from several institutions, including the Hospital Clínico Universitario de Valencia, the Hospital Universitario Germans Trias i Pujol, and Hospital del Mar. Dr. Alexandre Calon, a principal investigator and coordinator of the Translational Research Group in tumor Microenvironment at HMRIB, noted that “the validated marker maintains strong predictive and prognostic performance across patient cohorts.”
Expanding the Reach of Immunotherapy
One of the most significant clinical implications of the CTHRC1(+) CAF marker is its potential to expand the use of immunotherapy. Currently, immunotherapy—which leverages the body’s own immune system to fight cancer—is applicable to only a small fraction of colorectal cancer patients, estimated at around 5%. Even within that group, the treatment is not universally effective.
The new biomarker allows doctors to assess the state of immune cells within the tumor and their ability to attack neoplastic cells. This means the marker could identify “hidden” candidates for immunotherapy—patients who do not meet current eligibility criteria but whose tumor microenvironment suggests they would still benefit from the treatment.
Dr. Clara Montagut, Head of Section of the Medical Oncology Department at Hospital del Mar, explained that “this biomarker improves the selection of patients who could potentially benefit from immunotherapy,” which in turn helps guide more effective therapeutic strategies.
The Role of TGF-beta and Treatment Resistance
The study also sheds light on why some colorectal cancers are more resistant to treatment than others. The CTHRC1 protein is linked to the activity of a cytokine known as TGF-beta. In the context of the tumor microenvironment, TGF-beta is often associated with poorer disease outcomes and a higher likelihood of treatment failure.
When CTHRC1 levels are high, it typically indicates a high level of TGF-beta activity, which helps the tumor evade the immune system and resist chemotherapy. This discovery not only provides a prognostic tool but also identifies a potential new therapeutic target. If scientists can develop inhibitors that block the CTHRC1 protein, they may be able to “unlock” the tumor, making it more susceptible to existing treatments.
Dr. Eduard Batlle, an ICREA researcher at IRB Barcelona and member of CIBERONC, emphasized the link between basic science and clinical application, stating, “The identification of CTHRC1 as a TGF-beta-induced factor exemplifies how basic research can lead to clinically applicable biomarkers.”
Clinical Application and Accessibility
A critical hurdle for many new medical discoveries is the cost and complexity of the tests required to use them. However, the CTHRC1 marker is designed for accessibility. It can be detected using immunohistochemistry (IHC) tests—a standard procedure already available in almost every hospital pathology department.
This means that once the marker is integrated into routine clinical practice, there will be no necessitate for expensive new machinery or specialized laboratories. Dr. Mar Iglesias, first author of the study and Head of the Pathology Department at Hospital del Mar, noted that the results position CTHRC1(+) CAFs as a tool that can be integrated into routine services to facilitate guide the selection of the most appropriate treatment for each patient.
| Feature | Traditional Biomarkers | CTHRC1(+) CAF Marker |
|---|---|---|
| Primary Focus | Genetic mutations within tumor cells | Non-tumor cells (Fibroblasts) |
| Immunotherapy Scope | Limited to ~5% of patients | Potential to identify more candidates |
| Diagnostic Tool | Often requires NGS or complex assays | Standard Immunohistochemistry (IHC) |
| Prognostic Insight | Tumor grade/stage | TGF-beta activity & resistance levels |
Whereas the primary focus of this research was colorectal cancer, the team suggests that the presence of CTHRC1(+) CAFs may have implications for other malignancies. The potential for this biomarker to be applied to breast and lung cancers is currently an area of interest for further study.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their healthcare provider for diagnosis and treatment options.
The next phase for this research involves further investigation into CTHRC1 inhibitors to determine if blocking this protein can actively reverse treatment resistance in clinical trials. Official updates on the integration of this marker into standard pathology protocols are expected as the findings move from validation to clinical implementation.
Do you have questions about the future of precision oncology? Share this article and join the conversation in the comments below.
